Physician profile
Ryan M Mobley
NPI 1720022767
$21,716.51
in general payments reported to CMS, 2019-2025
67 companies · $6,012 in 2025
The $6,012 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,919 · 2022: $3,460 · 2023: $3,956 · 2024: $4,371 · 2025: $6,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,219.84 |
| Education | $118.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,607.90 | 2021-2025 | Imfinzi, Datroway, Tagrisso |
| Novartis Pharmaceuticals Corporation | $1,442.70 | 2021-2025 | |
| Incyte Corporation | $1,190.32 | 2021-2025 | Jakafi, Niktimvo, Monjuvi |
| Genentech USA, INC. | $1,104.30 | 2021-2025 | Polivy, Tecentriq, Alecensa |
| Daiichi Sankyo INC. | $1,046.45 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $1,043.67 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $952.03 | 2021-2025 | Opdivo, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $892.11 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $880.39 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $782.43 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Glaxosmithkline, LLC. | $770.94 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Abbvie INC. | $670.36 | 2021-2025 | |
| Celgene Corporation | $591.59 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Genzyme Corporation | $569.60 | 2021-2025 | |
| Sobi, INC | $507.61 | 2022-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $495.74 | 2021-2023 | Imbruvica, Epkinly |
| Amgen INC. | $423.12 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Astellas Pharma US INC | $418.42 | 2021-2025 | Padcev, Xtandi, Vyloy |
| Lilly USA, LLC | $398.23 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Alexion Pharmaceuticals, INC. | $387.71 | 2022-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $348.86 | 2021-2025 | |
| Eisai INC. | $340.83 | 2022-2025 | |
| Array Biopharma INC | $328.62 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $308.07 | 2024-2025 | Fruzaqla, Iclusig, Alunbrig |
| Gilead Sciences, INC. | $279.76 | 2021-2025 | Trodelvy |
| Tersera Therapeutics LLC | $266.98 | 2021-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $224.05 | 2021-2025 | Onivyde, Somatuline Depot, Tazverik |
| Emd Serono, INC. | $222.45 | 2021-2025 | Tepmetko |
| Sumitomo Pharma America, INC. | $220.90 | 2024-2025 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $214.41 | 2021-2025 | Libtayo |
| Blueprint Medicines Corporation | $196.70 | 2021-2025 | Ayvakit |
| Karyopharm Therapeutics INC. | $178.04 | 2022-2025 | Xpovio |
| Puma Biotechnology, INC. | $174.60 | 2021-2024 | Nerlynx |
| Adc Therapeutics America, INC. | $160.21 | 2022-2025 | |
| Genmab U.S., INC. | $149.33 | 2023-2025 | Epkinly, Tivdak |
| Beone Medicines USA, INC. | $136.32 | 2025 | Tevimbra, Brukinsa |
| Rigel Pharmaceuticals, INC. | $125.60 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Jazz Pharmaceuticals INC. | $123.97 | 2021-2025 | |
| Exelixis INC. | $123.66 | 2024-2025 | Cabometyx |
| Kyowa Kirin, INC. | $121.25 | 2021-2025 | Poteligeo |
| Adaptive Biotechnologies Corporation | $90.80 | 2022-2024 | Clonoseq |
| Sun Pharmaceutical Industries INC. | $86.71 | 2022-2023 | Yonsa, Odomzo |
| Aveo Pharmaceuticals, INC. | $78.26 | 2022-2025 | |
| Deciphera Pharmaceuticals INC. | $74.09 | 2021-2025 | Romvimza, Qinlock |
| Eusa Pharma (US) LLC | $71.35 | 2021 | |
| Morphosys, US INC. | $68.97 | 2021-2023 | Monjuvi |
| Stemline Therapeutics INC. | $65.98 | 2024 | Orserdu |
| Springworks Therapeutics, INC. | $64.88 | 2024-2025 | Ogsiveo |
| Syndax Pharmaceuticals, INC. | $58.40 | 2025 | Revuforj |
| Mirati Therapeutics, INC. | $57.93 | 2023 | Krazati |
| Taiho Oncology, INC. | $55.22 | 2021 | |
| Coherus Oncology, INC. | $51.91 | 2024-2025 | Loqtorzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.52 | 2021-2024 | |
| Beigene USA, INC. | $47.68 | 2023-2024 | Brukinsa |
| Pharmaessentia USA Corporation | $44.61 | 2025 | Besremi |
| G1 Therapeutics, INC. | $43.71 | 2022-2023 | Cosela |
| Clovis Oncology, INC. | $38.58 | 2021 | |
| Global Blood Therapeutics, INC. | $33.35 | 2021-2022 | |
| Kite Pharma, INC. | $27.89 | 2025 | Yescarta |
| Recordati_rare_diseases_inc. | $26.90 | 2024 | Sylvant |
| Acrotech Biopharma INC. | $26.82 | 2025 | Beleodaq |
| Legend Biotech USA INC. | $25.02 | 2025 | Carvykti |
| Servier Pharmaceuticals LLC | $24.64 | 2024 | |
| Azurity Pharmaceuticals, INC. | $24.56 | 2025 | Danziten |
| Cti Biopharma Corp. | $23.84 | 2023 | Vonjo |
| Novocure INC. | $20.15 | 2022 | |
| Tolmar, INC. | $13.51 | 2023 |
Drugs and devices associated with these payments
Imbruvica $641Keytruda $590Jakafi $557Orgovyx $469Epkinly $464Ojjaara $443Opdivo $386Enhertu $381Xtandi $338Imfinzi $325Polivy $324Lenvima $300Tecentriq $295Padcev $277Alecensa $266Verzenio $261Ultomiris $243Zoladex $243Gavreto $241Tukysa $231Elrexfio $221Venclexta $218Rozlytrek $213Reblozyl $213Injectafer $208Talzenna $200Darzalex $199Braftovi $198Adcetris $198Tecvayli $195Lynparza $185Datroway $181Fruzaqla $172Mektovi $168Zejula $163Jaypirca $162Kisqali $162Stivarga $154Vitrakvi $154Talvey $143Pluvicto $140Lutathera $131Ibrance $130Fabhalta $130Doptelet $130Scemblix $130Rybrevant $129Vonjo $129Jemperli $127Ayvakit $126Libtayo $125Cabometyx $124Wayrilz $122Pomalyst $115Lorbrena $115Opdualag $105Zynlonta $98.47Erleada $97.74Piqray $96.68Brukinsa $92.70Onivyde $91.32Tevimbra $91.30Paxlovid $90.60Poteligeo $89.80Jevtana $88.34Xpovio $86.14Rezlidhia $85.58Tavalisse $85.58Nubeqa $82.78Comirnaty $75.21Lunsumio $74.73Columvi $74.73Nplate $73.85Xgeva $73.85Vectibix $73.85Clonoseq $73.85Promacta $70.04Monjuvi $67.61Orserdu $65.98Ogsiveo $64.88Zepzelca $63.49Fotivda $62.03Krazati $57.93Inlyta $57.37Vanflyta $56.03Trodelvy $55.96Cablivi $55.39Enjaymo $55.39Romvimza $54.23Qinlock $54.23Niktimvo $54.20Mekinist $53.71Tivdak $53.48Odomzo $53.33Yonsa $53.33Keytruda Qlex $51.63Retevmo $51.56Itovebi $51.18Somatuline Depot $50.57Tasigna $49.44
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Mobley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.